Case Report

Rare gastrointestinal presentation of systemic mastocytosis, a case report

Arezoo Eftekhar Javadi, Elham Nazar *, Niousha Momeni

* Corresponding author. Sina hospital, Tehran University of medical sciences, Iran.

A R T I C L E  I N F O

Keywords:
Mastocytosis
Gastrointestinal
Abdominal pain

A B S T R A C T

Introduction: Systemic mastocytosis is a rare disease resulting from infiltration of atypical mast cells in multiple organ systems and present with variety of symptoms. Primary appendiceal and cecal mass with isolated abdominal pain as a presenting feature in systemic mastocytosis have not been reported in literature up to now. Case report: We described a 69- years-old female with systemic mastocytosis who presented with chronic abdominal pain and recent progression. On imaging of the abdomen and pelvis showed a mass in cecum. The patient underwent surgery and histopathologic evaluation of cecal and appendiceal masses revealed uniform small round cell tumor with eosinophilic cytoplasm admixed with many eosinophils distorting normal colonic mucosal architecture. The neoplastic cells showed positive expression of CD117 and Mast cell tryptase. According to all these considerations systemic mastocytosis was confirmed as the diagnosis. Conclusion: Isolated abdominal pain and primary large intestinal mass are uncommon features of systemic mastocytosis. This case report informed physicians and pathologists to consider it as one of differential diagnosis.

1. Background

Mastocytosis is an uncommon neoplastic infiltration of mast cells in one or multiple organs. Majority of patients with Mastocytosis have evidence of cutaneous involvement and less of them present with other organs involvement include the spleen, lymph nodes, liver and gastrointestinal (GI) tract [1]. Mastocytosis is a clinically and pathologically heterogenous disease [2]. Mastocytosis is a quite uncommon disorder and underdiagnosed for its nonspecific findings with little data about the epidemiology [3]. Up to now, little is described about the frequency and occurrence of mastocytosis. An overall incidence estimated 0.9 per 100, 000 per year [4]. According to new update of World health organization (WHO), Mastocytosis classified in three variants: cutaneous Mastocytosis, systemic Mastocytosis and mastcell sarcoma [5]. Releasing mast cells mediators is the main etiology for presenting clinical manifestations of systemic Mastocytosis, also accumulation and infiltration of mast cells in the tissue introduced as another reason [6]. Diagnosis is based on findings of atypical mast cells infiltration in histopathologic evaluation associated with presence of C-Kit mutation or persistent elevation of serum Tryptase level [5]. If the GI manifestations present as the only symptom, because of its non specificity, diagnosis of systemic Mastocytosis would be extremely difficult and simply ignored. Here we report an unusual case of Mastocytosis presented by isolated abdominal pain and simultaneous cecal and appendiceal masses without any symptoms or signs. This case report has been reported in line with the SCARE Criteria [7].

2. Case presentation

A 63- years-old woman with chief complaint of chronic abdominal pain and recent worsening referred to surgery department of Sina hospital affiliated to Tehran University of Medical Sciences in November 2019. She didn’t have complained any other symptoms such as nausea, vomiting, diarrhea, loss of appetite, weight loss, skin rashes or flushing. In physical examination, vital signs were normal. Abdomen was soft in palpation without any tenderness and appearance abnormalities. Cardiopulmonary, skin and other organ systems examination were unremarkable. She had no familial history, past medical, and past surgical history. Laboratory analysis showed mild leukocytosis, other hematologic, biochemical and urine tests were all unremarkable. On imaging, one mass in cecum was seen. Patient was scheduled for right hemicolectomy and para-aortic lymph node dissection by expert colorectal surgeon. The specimen was received at Sina hospital pathology lab for histopathologic examination consists of a segment of colon, cecum, terminal ileum and appendix. Colon and terminal ileum were 26cm in length and 4.5cm in maximum diameter. On opening a whitish solid submucosal mass was seen in cecum measuring 2x1.5 × 1cm. Also, a 0.7cm whitish lesion was noted in the base of appendix. Microscopic
Mastocytosis is a rare disease resulting infiltration and accumulation of a clonal, neoplastic proliferation of morphologically and immuno-phenotypically abnormal mast cells in one or multiple organ systems \[6\] cause different types of clinical manifestations ranging from skin limited symptoms particularly in pediatric cases to aggressive forms with extracutaneous involvement subsequent to organ failure associated with poor prognosis \[9-12\]. Systemic mastocytosis with multiple organs involvement generally occur in adult patients lacking skin manifestations which are similar to our case. The organ systems which involved in most cases of systemic mastocytosis are bone marrow, liver, spleen, GI tract and lymph nodes \[5\]. GI symptoms present in up to 80% of patients with systemic mastocytosis and abdominal pain is the most common GI symptom among them. The main etiology for these manifestations is the release of mast cell mediators, although in rare case of advanced systemic mastocytosis, infiltration of mast cells in GI mucosa introduced as the reason \[6,13-16\]. In our case, the main reason of GI symptoms was masses with mast cells infiltration. According to WHO diagnostic criteria when the major criteria and one minor criteria or at least three minor criteria are satisfied diagnosis of systemic mastocytosis could be made. The major criteria are the presence of multifocal, dense aggregation of at least 15 mast cells in bone marrow biopsy or another extra cutaneous organ. This is the most important part to establish systemic mastocytosis diagnosis while minor criteria determine just the clonal nature or aberrant phenotype of mast cells \[5,17-19\]. Diagnosis of systemic mastocytosis might be hard or underdiagnosed because of its multiple nonspecific manifestations especially when characteristic skin lesion is not present. As we described in our case when GI manifestations are isolated or predominant, diagnosis would be more challenging and simply ignored because of low incidence of systemic mastocytosis and wide range of diagnosis to be mentioned for patient who have simultaneous appendiceal and cecal mass presented with abdominal pain as the only symptom. According to literature review presentation of systemic mastocytosis with primary GI mast cell neoplasm haven’t been reported yet. This case report informed physicians and pathologists to consider this diagnosis for patients presented with chronic abdominal pain and large intestinal mass with isolated monotonous cells infiltration on microscopic examination to prevent mismanagement and morbidity. There is no definite treatment for systemic mastocytosis and available treatments are based on symptomatic control by avoidance of mast cell degranulation or inactivation of mast cells mediators. New treatment targets such as Kit mutations and other similar relevant options in neoplastic mast cells have been introduced in recent years \[14, 20-22\]. Although, definite diagnosis for Mastocytosis with unusual presentation is difficult, approaches for diagnosis and treatment devoid of any problem are serious.

### 4. Conclusion

Isolated Mastocytosis in the GI tract is rare but they must be careful in the differential diagnosis of various GI masses. Difficulties in the differential diagnosis might happen in connection with an unexpected setting. They reveal common surprising clinical signs that to conclude lead to inadequate treatment. It is our hope, that with such a report, we are able to reduce misdiagnosis and improve the outcome of these patients.

### Ethical approval

Ethical approval is not needed due to the fact that the treatment of the patient was based on approved options and was not controversial.

### Sources of funding

No source to be stated.

### Authors’ contributions

AEJ: major contribution of the idea, study design and revise the paper, EN: pathologist and writing the paper, NM: data collection and follow up.

### Registration of research studies

- Name of the registry: Unique Identifying number or registration ID
- Hyperlink to your specific registration (must be publicly accessible and will be checked)

### Guarantor

Elham Nazar is Guarantor of this submission.

### Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the
written consent is available for review by the Editor-in-Chief of this journal on request.

Provenance and peer review
Not commissioned, externally peer-reviewed.

Declaration of competing interest
There is no conflict to be declared.

Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.org/10.1016/j.amsu.2022.104196.

References
[1] J. Wang, et al., A Rare Case of Aggressive Systemic Mastocytosis involving the Gastrointestinal System and Review of Literature, 2021.
[2] L.A. Doyle, et al., A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients, Am. J. Surg. Pathol. 38 (6) (2014) 832.
[3] S.S. Cohen, et al., Epidemiology of systemic mastocytosis in Denmark, Br. J. Haematol. 166 (4) (2014) 521–528.
[4] J. Schwaab, et al., Importance of adequate diagnostic workup for correct diagnosis of advanced systemic mastocytosis, J. Allergy Clin. Immunol. Pract. 8 (9) (2020) 3121–3127, e1.
[5] I. Polyatskin, A. Artemyeva, Y.A. Krivolapov, Revised WHO classification of tumors of hematopoietic and lymphoid tissues, 2017: lymphoid tumors, Arkh. Patol. 81 (3) (2019) 59–65.
[6] H. Sokol, et al., Gastrointestinal involvement and manifestations in systemic mastocytosis, Inflamm. Bowel Dis. 16 (7) (2010) 1247–1253.
[7] R.A. Agha, et al., The SCARE 2020 guideline: updating consensus Surgical Case Report (SCARE) guidelines, Int. J. Surg. 84 (2020) 226–230.
[8] A. Pardanani, Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management, Am. J. Hematol. 94 (3) (2019) 363–377.
[9] A. Uzzaman, et al., Pediatric-onset mastocytosis: a long term clinical follow-up and correlation with bone marrow histopathology, Pediatr. Blood Cancer 53 (4) (2009) 629–634.
[10] J.M. Azaita, et al., Urticaria pigmentosa: a review of 67 pediatric cases, Pediatr. Dermatol. 11 (2) (1994) 102–106.
[11] B.V. Kettelhut, D.D. Metcalfe, Pediatric mastocytosis, Ann. Allergy 73 (3) (1994) 197–202; quiz 202.
[12] K.-H. Lim, et al., Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood, J. Am. Soc. Hematol. 113 (23) (2009) 5727–5736.
[13] R. Kirsch, et al., Systemic mastocytosis involving the gastrointestinal tract: clinicopathologic and molecular study of five cases, Mod. Pathol. 21 (12) (2008) 1508–1516.
[14] R.T. Jensen, Gastrointestinal abnormalities and involvement in systemic mastocytosis, Hematol./Oncol. Clin. 14 (3) (2000) 579–623.
[15] D.B. Ramsay, et al., Mast cells in gastrointestinal disease, Gastroenterol. Hepatol. 6 (12) (2010) 772.
[16] S.I. Siegert, et al., Are gastrointestinal mucosal mast cells increased in patients with systemic mastocytosis? Am. J. Clin. Pathol. 122 (4) (2004) 560–565.
[17] P. Valent, W.R. Sperr, C. Akin, How I treat patients with advanced systemic mastocytosis. Blood, J. Am. Soc. Hematol. 116 (26) (2010) 5812–5817.
[18] M.C. Onnes, L.K. Tanno, J.N.O. Elberink, Mast cell clonal disorders: classification, diagnosis and management, Curr. Treat. Options Allergy 3 (4) (2016) 453–464.
[19] M. Arock, et al., Current treatment options in patients with mastocytosis: status in 2015 and future perspectives, Eur. J. Haematol. 94 (6) (2015) 474–490.
[20] H.D. Pettigrew, et al., Contemporary challenges in mastocytosis, Clin. Rev. Allergy Immunol. 38 (2–3) (2010) 125–134.
[21] P. Valent, C. Akin, D.D. Metcalfe, Mastocytosis, Updated WHO classification and novel emerging treatment concepts. Blood, J. Am. Soc. Hematol. 129 (11) (2016) 1420–1427, 2017.
[22] L. Huang, et al., Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities: a case report, Medicine 95 (41) (2016).

Fig. 2. Immunohistochemical staining showed positive CD117 (left), LCA (middle), and tryptase (right) X200.